Mostra i principali dati dell'item
Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition
dc.creator | Skendros P., Papagoras C., Lefaki I., Giatromanolaki A., Kotsianidis I., Speletas M., Bocly V., Theodorou I., Dalla V., Ritis K. | en |
dc.date.accessioned | 2023-01-31T09:57:33Z | |
dc.date.available | 2023-01-31T09:57:33Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1111/bjd.14685 | |
dc.identifier.issn | 00070963 | |
dc.identifier.uri | http://hdl.handle.net/11615/79086 | |
dc.description.abstract | Generalized pustular psoriasis (GPP) is a severe type of psoriasis accompanied by systemic and often life-threatening manifestations. The efficacy of the interleukin (IL)-1 antagonist anakinra in cases of GPP underscores the role of IL-1 in disease pathogenesis. We present a case of a middle-aged man who developed an abrupt and severe form of GPP with severe eosinophilia and cholestatic hepatitis. The patient received salvage treatment with a combination of glucocorticoids, hydroxyurea and imatinib, while administration of the IL-1 inhibitor anakinra resulted in remission of hepatitis and a significant skin improvement. However, due to persistent hypersensitivity skin reactions, anakinra was withdrawn and replaced with the anti-IL-1β antagonist canakinumab. As a result of canakinumab, the patient's skin completely cleared, while no systemic manifestations recurred. After 1 year of continuous canakinumab therapy, the patient remained virtually free of symptoms, while the drug was well tolerated. © 2016 British Association of Dermatologists | en |
dc.language.iso | en | en |
dc.source | British Journal of Dermatology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84997113282&doi=10.1111%2fbjd.14685&partnerID=40&md5=9d1d4e99a2cf13479ebd6b3fc7a4feea | |
dc.subject | anakinra | en |
dc.subject | antibiotic agent | en |
dc.subject | canakinumab | en |
dc.subject | fresh frozen plasma | en |
dc.subject | glucocorticoid | en |
dc.subject | hydroxyurea | en |
dc.subject | imatinib | en |
dc.subject | interleukin 1beta | en |
dc.subject | methylprednisolone | en |
dc.subject | prednisolone | en |
dc.subject | canakinumab | en |
dc.subject | dermatological agent | en |
dc.subject | interleukin 1 receptor blocking agent | en |
dc.subject | interleukin 1beta | en |
dc.subject | monoclonal antibody | en |
dc.subject | adult | en |
dc.subject | Article | en |
dc.subject | case report | en |
dc.subject | Caucasian | en |
dc.subject | cholestasis | en |
dc.subject | cholestatic hepatitis | en |
dc.subject | diabetes mellitus | en |
dc.subject | drug dose reduction | en |
dc.subject | drug efficacy | en |
dc.subject | drug substitution | en |
dc.subject | drug tolerability | en |
dc.subject | drug withdrawal | en |
dc.subject | echography | en |
dc.subject | eosinophilia | en |
dc.subject | erythema | en |
dc.subject | erythroderma | en |
dc.subject | fever | en |
dc.subject | hepatitis B | en |
dc.subject | human | en |
dc.subject | hypereosinophilic syndrome | en |
dc.subject | hypersensitivity | en |
dc.subject | hypoalbuminemia | en |
dc.subject | jaundice | en |
dc.subject | lethargy | en |
dc.subject | leukocytosis | en |
dc.subject | low drug dose | en |
dc.subject | lymphadenopathy | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | nuclear magnetic resonance imaging | en |
dc.subject | priority journal | en |
dc.subject | pruritus | en |
dc.subject | psoriasis vulgaris | en |
dc.subject | pustular psoriasis | en |
dc.subject | pustule | en |
dc.subject | rash | en |
dc.subject | remission | en |
dc.subject | salvage therapy | en |
dc.subject | skin manifestation | en |
dc.subject | Staphylococcus infection | en |
dc.subject | topical treatment | en |
dc.subject | treatment response | en |
dc.subject | urticaria | en |
dc.subject | antagonists and inhibitors | en |
dc.subject | chemically induced | en |
dc.subject | psoriasis | en |
dc.subject | treatment outcome | en |
dc.subject | Antibodies, Monoclonal | en |
dc.subject | Dermatologic Agents | en |
dc.subject | Humans | en |
dc.subject | Interleukin 1 Receptor Antagonist Protein | en |
dc.subject | Interleukin-1beta | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Psoriasis | en |
dc.subject | Treatment Outcome | en |
dc.subject | Blackwell Publishing Ltd | en |
dc.title | Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |